伟思医疗 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	400.0M	462.0M	322.0M	430.0M	378.0M
Revenue Growth %	-13.4%	43.5%	-25.1%	13.8%	--
Total Revenue	400.0M	462.0M	322.0M	430.0M	378.0M
Cost Of Revenue	138.0M	149.0M	88.5M	108.0M	99.8M
+Gross Profit	262.0M	313.0M	233.5M	322.0M	278.2M
Gross Margin %	65.5%	67.7%	72.5%	74.9%	73.6%
Total Operating Cost	326.0M	349.0M	248.0M	278.0M	239.0M
Selling Expenses	94.4M	105.0M	91.5M	78.1M	72.1M
Admin Expenses	44.5M	47.5M	38.2M	38.0M	33.8M
Rd Expenses	50.6M	57.7M	43.7M	63.5M	34.3M
Finance Expenses	-8.4M	-18.0M	-18.9M	-16.6M	-6.0M
+Operating Income	112.0M	148.0M	104.0M	195.0M	165.0M
Operating Margin %	28.0%	32.0%	32.3%	45.3%	43.7%
Non Operating Income	1.8M	1.6M	1.4M	2.8M	1.5M
Non Operating Expenses	70,800	42,300	44,400	49,200	280,200
Investment Income	11.3M	10.6M	16.0M	20.6M	13.4M
Fair Value Change Income	2.4M	-964,000	--	--	--
Asset Disposal Income	3,900	-2,100	--	--	49,800
Asset Impairment Loss	29,200	--	--	--	3,300
Other Income	23.8M	25.8M	14.5M	21.9M	12.3M
Income Before Tax	113.0M	150.0M	106.0M	197.0M	166.0M
Income Tax	11.3M	13.8M	12.0M	19.8M	22.9M
+Net Income	102.0M	136.0M	93.8M	178.0M	143.0M
Net Margin %	25.5%	29.4%	29.1%	41.4%	37.8%
Net Income Attributable	102.0M	136.0M	93.8M	178.0M	144.0M
Minority Interest	--	--	--	-275,300	-525,000
Eps Basic	1.07	1.43	1.37	2.60	2.46
Eps Diluted	1.07	1.42	1.37	2.59	2.46

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	1.1B	1.2B	1.2B	1.4B	1.4B
Accounts Receivable	25.2M	36.6M	21.1M	24.3M	12.9M
Notes And Accounts Receivable	25.2M	36.6M	21.1M	24.3M	12.9M
Prepayments	6.0M	5.8M	3.1M	1.8M	998,000
Inventory	38.7M	39.9M	34.8M	30.4M	37.1M
Total Current Assets	1.2B	1.3B	1.3B	1.4B	1.4B
Fixed Assets	--	96.1M	100.0M	94.8M	98.3M
Fixed Assets Total	87.8M	96.1M	100.0M	94.8M	98.3M
Construction In Progress	--	225.0M	70.4M	2.5M	--
Construction In Progress Total	320.0M	225.0M	70.4M	2.5M	--
Intangible Assets	122.0M	109.0M	88.9M	18.8M	20.0M
Long Term Deferred Expenses	2.1M	1.2M	2.6M	768,800	1.1M
Total Non Current Assets	657.0M	551.0M	365.0M	204.0M	122.0M
Total Assets	1.8B	1.8B	1.7B	1.6B	1.5B
Accounts Payable	19.4M	18.0M	19.7M	9.3M	9.9M
Advance Receipts	1.2M	1.2M	1.6M	1.6M	1.1M
Contract Liabilities	3.6M	5.1M	11.9M	31.7M	61.5M
Total Current Liabilities	192.0M	152.0M	129.0M	104.0M	129.0M
Long Term Borrowings	--	--	--	--	--
Total Non Current Liabilities	1.3M	27.6M	26.4M	1.8M	776,200
Total Liabilities	193.0M	179.0M	156.0M	106.0M	129.0M
Paid In Capital	95.8M	68.6M	68.6M	68.3M	68.3M
Capital Reserve	1.1B	1.1B	1.1B	1.1B	1.1B
Surplus Reserve	44.6M	34.3M	34.3M	34.2M	34.2M
Retained Earnings	428.0M	438.0M	349.0M	344.0M	238.0M
Minority Equity	--	--	--	--	5.0M
Equity Attributable	1.6B	1.6B	1.5B	1.5B	1.4B
Total Equity	1.6B	1.6B	1.5B	1.5B	1.4B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	458.0M	493.0M	341.0M	447.0M	411.0M
Tax Refunds Received	15.5M	20.5M	7.0M	12.4M	8.8M
Total Operating Cash Inflow	498.0M	545.0M	380.0M	492.0M	435.0M
Cash Paid For Goods	115.0M	138.0M	75.5M	112.0M	119.0M
Cash Paid To Employees	151.0M	150.0M	122.0M	109.0M	89.1M
Taxes Paid	60.0M	62.3M	47.1M	62.9M	52.2M
Total Operating Cash Outflow	379.0M	411.0M	294.0M	335.0M	314.0M
Operating Cash Flow	118.0M	134.0M	86.2M	157.0M	121.0M
Total Investing Cash Inflow	2.8B	2.5B	3.7B	4.3B	2.1B
Total Investing Cash Outflow	2.9B	2.7B	3.8B	4.4B	2.1B
Investing Cash Flow	-101.0M	-164.0M	-105.0M	-76.8M	1.9M
Cash From Borrowings	--	--	--	--	--
Dividends And Interest Paid	102.0M	51.0M	88.9M	71.8M	50.3M
Debt Repayments	--	--	--	--	14.0M
Total Financing Cash Inflow	13.3M	--	10.8M	--	1.1B
Total Financing Cash Outflow	117.0M	64.0M	106.0M	81.0M	82.5M
Financing Cash Flow	-104.0M	-64.0M	-95.0M	-81.0M	995.0M
Net Change In Cash	-86.6M	-93.9M	-114.0M	-412,800	1.1B
Ending Cash Balance	1.1B	1.2B	1.2B	1.4B	1.4B
Capex	113.0M	133.0M	95.6M	87.3M	11.7M